Clinical Trial Results: A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) [Phase 3]

View source ↗

Summary

Phase 3 study results for rocatinlimab monotherapy in moderate-to-severe atopic dermatitis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (AMG 451) (Rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2026-06-26